Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis.
OBJECTIVE
To compare the effects of blood glucose lowering regimens in groups of patients categorized by baseline age and diagnosed age.


METHODS
Placebo-controlled randomized trials in type 2 diabetes patients with a study length ≥12 weeks were included.


RESULTS
A total of 246 trials were included. HbA1c changes from baseline corrected by placebo were comparable in sulfonylurea treatment between older and younger patients' groups (weighted mean difference (WMD), -1.28% vs -0.92%, p > 0.05). Treatment with metformin between groups resulted in a comparable change in HbA1c levels (WMD, -0.97% vs -1.23%, p > 0.05). Treatment with α-glucosidase inhibitor (WMD, -0.68% vs -0.67%, p > 0.05), treatment with thiazolidinedione (WMD, -0.74% vs -1.01%, p > 0.05), treatment with DPP-4 inhibitors (WMD, -0.67% vs -0.67%, p > 0.05), and treatment with SGLT2 inhibitors (WMD, -0.54% vs -0.67%, p > 0.05) between groups also resulted in comparable HbA1c changes. Treatment with GLP-1 analogs between groups in HbA1c changes were also comparable (p > 0.05). Regression analysis indicated that the baseline age or diagnosed age was not associated with the HbA1c changes from baseline.


CONCLUSIONS
In each hypoglycemic treatment, the baseline age or diagnosed age was not associated with the HbA1c changes from baseline.
a Endocrine & Metabolism Department , Peking University People's Hospital , Beijing , China.
Xiaoling
X
Cai
a Endocrine & Metabolism Department , Peking University People's Hospital , Beijing , China.
Wenjia
W
Yang
a Endocrine & Metabolism Department , Peking University People's Hospital , Beijing , China.
Yifei
Y
Chen
a Endocrine & Metabolism Department , Peking University People's Hospital , Beijing , China.
Xueying
X
Gao
a Endocrine & Metabolism Department , Peking University People's Hospital , Beijing , China.
Lingli
L
Zhou
a Endocrine & Metabolism Department , Peking University People's Hospital , Beijing , China.
Simin
S
Zhang
a Endocrine & Metabolism Department , Peking University People's Hospital , Beijing , China.
Xueyao
X
Han
a Endocrine & Metabolism Department , Peking University People's Hospital , Beijing , China.
Linong
L
Ji
D000367:Age Factors; D001786:Blood Glucose / Q000032:analysis; D000068456:Clinical Studies as Topic; D016208:Databases, Factual; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000032:analysis; D065089:Glycoside Hydrolase Inhibitors / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D015990:Placebo Effect; D012044:Regression Analysis; D045162:Thiazolidinediones / Q000627:therapeutic use
D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; C089946:2,4-thiazolidinedione
Age; HbA1c; diagnosed age; type 2 diabetes mellitus